A Randomized Trial of Sitagliptin and Spironolactone With Combination Therapy in Hospitalized Adults With COVID-19

CONTEXT: COVID-19 may cause respiratory distress syndrome and death. Treatment of COVID-19 to prevent complications remains a priority. OBJECTIVE: Our investigation sought to determine whether combination of spironolactone and sitagliptin could reduce mortality for inpatients with SARS-CoV-2 infecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Abbasi, Farhad, Adatorwovor, Reuben, Davarpanah, Mohammad Ali, Mansoori, Yasaman, Hajiani, Mehdi, Azodi, Farzan, Sefidbakht, Sepideh, Davoudi, Shayesteh, Rezaei, Farzana, Mohammadmoradi, Shayan, Asadipooya, Kamyar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898039/
https://www.ncbi.nlm.nih.gov/pubmed/35261932
http://dx.doi.org/10.1210/jendso/bvac017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898039/
https://www.ncbi.nlm.nih.gov/pubmed/35261932
http://dx.doi.org/10.1210/jendso/bvac017

Ejemplares similares